These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25926499)

  • 1. Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
    Larrat S; Vallet S; David-Tchouda S; Caporossi A; Margier J; Ramière C; Scholtes C; Haïm-Boukobza S; Roque-Afonso AM; Besse B; André-Garnier E; Mohamed S; Halfon P; Pivert A; LeGuillou-Guillemette H; Abravanel F; Guivarch M; Mackiewicz V; Lada O; Mourez T; Plantier JC; Baazia Y; Alain S; Hantz S; Thibault V; Gaudy-Graffin C; Bouvet D; Mirand A; Henquell C; Gozlan J; Lagathu G; Pronier C; Velay A; Schvoerer E; Trimoulet P; Fleury H; Bouvier-Alias M; Brochot E; Duverlie G; Maylin S; Gouriou S; Pawlotsky JM; Morand P
    J Clin Microbiol; 2015 Jul; 53(7):2195-202. PubMed ID: 25926499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure.
    Mohamed S; Bourliere M; Benali S; Oules V; Castellani P; Khiri H; Camus C; Penaranda G; Chiche L; Gonzalez D; Sayada C; Olive D; Halfon P
    J Clin Virol; 2016 May; 78():36-43. PubMed ID: 26971166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study.
    Hoffmann L; Ramos JA; Souza EV; Araújo Ramos AL; Villela-Nogueira CA; Urményi TP; Tanuri A; Rondinelli E; Silva R
    Virol J; 2013 Feb; 10():57. PubMed ID: 23409973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure.
    Macartney MJ; Irish D; Bridge SH; Garcia-Diaz A; Booth CL; McCormick AL; Labbett W; Smith C; Velazquez C; Tanwar S; Trembling P; Jacobs M; Dusheiko G; Rosenberg W; Haque T
    Antiviral Res; 2014 May; 105():112-7. PubMed ID: 24594347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.
    Barnard RJ; Howe JA; Ogert RA; Zeuzem S; Poordad F; Gordon SC; Ralston R; Tong X; Sniukiene V; Strizki J; Ryan D; Long J; Qiu P; Brass CA; Albrecht J; Burroughs M; Vuocolo S; Hazuda DJ
    Virology; 2013 Sep; 444(1-2):329-36. PubMed ID: 23876458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
    Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
    Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
    Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.
    Ogert RA; Howe JA; Vierling JM; Kwo PY; Lawitz EJ; McCone J; Schiff ER; Pound D; Davis MN; Gordon SC; Ravendhran N; Rossaro L; Jacobson IM; Ralston R; Chaudhri E; Qiu P; Pedicone LD; Brass CA; Albrecht JK; Barnard RJ; Hazuda DJ; Howe AY
    Antivir Ther; 2013; 18(3):387-97. PubMed ID: 23406826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
    Zhang Y; Cao Y; Zhang R; Zhang X; Lu H; Wu C; Huo N; Xu X
    PLoS One; 2016; 11(11):e0165658. PubMed ID: 27812165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P; Reddy KR
    Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C.
    Sargin Altunok E; Sayan M; Akhan S; Aygen B; Yildiz O; Tekin Koruk S; Mistik R; Demirturk N; Ural O; Kose Ş; Aynioglu A; Korkmaz F; Ersoz G; Tuna N; Ayaz C; Karakecili F; Keten D; Inan D; Yazici S; Koculu S; Yildirmak T
    Int J Infect Dis; 2016 Sep; 50():1-5. PubMed ID: 27401586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
    Asselah T
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):455-62. PubMed ID: 23199504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.
    De Meyer S; Dierynck I; Ghys A; Beumont M; Daems B; Van Baelen B; Sullivan JC; Bartels DJ; Kieffer TL; Zeuzem S; Picchio G
    Hepatology; 2012 Dec; 56(6):2106-15. PubMed ID: 22806681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.
    Sølund C; Krarup H; Ramirez S; Thielsen P; Røge BT; Lunding S; Barfod TS; Madsen LG; Tarp B; Christensen PB; Gerstoft J; Laursen AL; Bukh J; Weis N;
    PLoS One; 2014; 9(12):e113034. PubMed ID: 25438153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2013 Jun; 85(6):1028-36. PubMed ID: 23588728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.